The promise of Medicare’s MolDx program to provide greater reimbursement consistency and to fully reflect the value of molecular diagnostics has yet to be fulfilled, laboratory representatives argued at a diagnostics summit last month.
The Molecular Diagnostic Services, or MolDx, process for assessing CPT codes for reimbursement of lab tests “is taking more time...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?